BO
BOLD.US Boundless Bio, Inc. Common Stock
- Market cap
- USD 59.0M
- P/E
- -
- P/B
- 0.94x
- ROE
- -92.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BOLD.US undervalued?
Graham numberThe Graham number of Boundless Bio, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Boundless Bio, Inc. Common Stock fundamental analysis
No fundamental analysis for Boundless Bio, Inc. Common Stock yet.
Boundless Bio, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Boundless Bio, Inc. Common Stock
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer lumina…
Full company profileBoundless Bio, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Boundless Bio, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | -682K | -942K | -957K | -1.09M | -1.25M | - |
| Operating Income | -60.0M | -93.2M | -134M | -25.3M | -46.5M | -54.8M | -73.3M | -63.6M | -60.1M |
| EBITDA | -58.1M | -88.7M | -121M | -24.5M | -45.0M | -48.5M | -64.3M | -56.9M | -54.6M |
| Net Income | -59.7M | -90.2M | -129M | -25.2M | -45.9M | -49.4M | -65.4M | -58.2M | -56.8M |
| EPS | -5.59 | -3.40 | -2.93 | -1.13 | -2.06 | -2.22 | -3.85 | -2.60 | -2.48 |
| Balance Sheet | |||||||||
| Total Assets | 142M | 179M | 473M | 114M | 76.8M | 130M | 206M | 157M | 63.6M |
| Total Liabilities | 22.7M | 22.1M | 29.8M | 152M | 159M | 257M | 55.8M | 58.4M | 1.87M |
| Shareholders' Equity | 119M | 157M | 443M | -38.2M | -81.7M | -127M | 151M | 98.7M | 61.7M |
| Cash & Short-term Investments | 105M | 134M | 414M | 73.0M | 66.7M | 121M | 152M | 108M | 62.9M |
| Total Debt | 2.75M | 7.18M | 7.07M | 377K | 5.18M | 2.20M | 47.6M | 49.0M | - |
| Cash Flow | |||||||||
| Operating Cash Flow | -49.0M | -84.5M | -108M | -23.2M | -39.6M | -46.9M | -60.8M | -46.7M | -62.4M |
| Capital Expenditure | 16.7M | 7.55M | 11.6M | 2.03M | 1.07M | 633K | 2.54M | 546K | 61.3K |
| Free Cash Flow | -65.7M | -92.1M | -120M | -25.3M | -40.7M | -47.5M | -63.4M | -47.2M | -62.5M |
| Ratios | |||||||||
| ROE | -50.0% | -57.6% | -29.1% | - | - | - | -43.4% | -59.0% | -92.1% |
| ROA | -42.0% | -50.5% | -27.3% | -22.2% | -59.7% | -38.1% | -31.7% | -37.1% | -89.3% |
| Debt to Equity | 0.02x | 0.05x | 0.02x | - | - | - | 0.32x | 0.50x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Boundless Bio, Inc. Common Stock dividends
Boundless Bio, Inc. Common Stock has not paid dividends in the last 8 fiscal years.
Who owns Boundless Bio, Inc. Common Stock
- Insiders 12.12%
- Institutions 66.86%
- Public & others 21.01%
- Shares outstanding 23.6M
- Free float 16.4M
Top funds holding BOLD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 899K | 3.88% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 445K | 1.92% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 228K | 0.98% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 193K | 0.83% | -3.30% | Aug 2026 |
| Bridgeway Ultra-Small Company | 77.5K | 0.33% | 0.00% | Jun 2026 |
| Fidelity Extended Market Index | 76.4K | 0.33% | +12.92% | Sep 2026 |
| iShares Micro-Cap ETF | 53.4K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 19.0K | 0.08% | 0.00% | Sep 2026 |
| China Universal Gbl YLBJ QDII CNH | 16.9K | 0.07% | 0.00% | Jun 2026 |
| Vanguard U.S. Eq Idx £ Acc | 10.6K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 8.95K | 0.04% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 4.09K | 0.02% | 0.00% | Sep 2026 |
| JHVIT Total Stock Market Index I | 883.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding BOLD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARCH VENTURE CORP | 2.69M | 11.66% | 0.00% | Jun 2026 |
| FMR Inc | 2.58M | 11.17% | -4.24% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 2.56M | 11.08% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 1.97M | 8.52% | 0.00% | Jun 2026 |
| Cormorant Asset Management, LLC | 1.00M | 4.33% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 615K | 2.66% | +2.97% | Jun 2026 |
| Wellington Management Company LLP | 556K | 2.41% | 0.00% | Jun 2026 |
| Millennium Management LLC | 479K | 2.07% | +379.24% | Jun 2026 |
| Renaissance Technologies Corp | 472K | 2.04% | +18.19% | Jun 2026 |
| Alyeska Investment Group, L.P. | 300K | 1.30% | 0.00% | Jun 2026 |
| Affinity Asset Advisors, LLC | 250K | 1.08% | 0.00% | Jun 2026 |
| RBF LLC | 200K | 0.87% | 0.00% | Jun 2026 |
| Ensign Peak Advisors Inc | 160K | 0.69% | -14.75% | Jun 2026 |
| Stonepine Capital Management Llc | 155K | 0.67% | -74.13% | Jun 2026 |
| Acadian Asset Management LLC | 147K | 0.64% | +1,063.81% | Jun 2026 |
| Citadel Advisors Llc | 145K | 0.63% | -89.19% | Jun 2026 |
| Bridgeway Capital Management, LLC | 128K | 0.55% | +153.47% | Jun 2026 |
| Geode Capital Management, LLC | 117K | 0.51% | -8.50% | Jun 2026 |
| HRT FINANCIAL LLC | 116K | 0.50% | 0.00% | Jun 2026 |
| BlackRock Inc | 88.5K | 0.38% | +25.21% | Jun 2026 |
Boundless Bio, Inc. Common Stock company profile
- Company name
- Boundless Bio, Inc. Common Stock
- Ticker
- BOLD.US
- Exchange
- USA Stocks
- Listed since
- Mar 28, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Fiscal year end
- December
- Address
- 10955 Alexandria Way, San Diego, CA, United States, 92121
- Phone
- 858 766 9912
- Website
- boundlessbio.com
About Boundless Bio, Inc. Common Stock
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Boundless Bio, Inc. Common Stock management
3- Ms. Jessica Oien J.D.President, Principal Executive Officer, Chief Legal Officer & Corporate Secretary · born 1971
- Mr. David HinkleSenior VP of Finance, Controller & Corporate Treasurer · born 1962
- Ms. Meredith WesleyChief Human Resources Officer